Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-003854
Filing Date
2025-01-10
Accepted
2025-01-10 09:00:07
Documents
1
Period of Report
2025-01-08

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 8719
  Complete submission text file 0000950170-25-003854.txt   10141
Mailing Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215
Business Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215 (978) 501-3026
Verve Therapeutics, Inc. (Issuer) CIK: 0001840574 (see all company filings)

EIN.: 824800132 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 500 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Business Address
Kathiresan Sekar (Reporting) CIK: 0001864112 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-40489 | Film No.: 25520679